# An Open-label, Multinational, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam

> **NCT00761774** · PHASE3 · COMPLETED · sponsor: **UCB Pharma** · enrollment: 108 (actual)

## Conditions studied

- Epilepsy

## Interventions

- **DRUG:** Brivaracetam

## Key facts

- **NCT ID:** NCT00761774
- **Lead sponsor:** UCB Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11
- **Primary completion:** 2017-03
- **Final completion:** 2017-03
- **Target enrollment:** 108 (ACTUAL)
- **Last updated:** 2018-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00761774

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00761774, "An Open-label, Multinational, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00761774. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*